Endometriosis reduces opioid receptors (by 20%) and NMDA receptors (by 40%) in the brain's pain center without changing natural painkiller levels, potentially explaining why endometriosis pain is so hard to treat.
40% fewer pain receptorsEndometriosis reduced NMDA receptor expression in the brain's pain-modulation center by 40%, revealing that the disease physically alters brain pain circuitry
What the researchers found
In a rat model of endometriosis, the condition caused significant changes in the brain's pain-processing center — the periaqueductal gray (PAG). After 60 days of endometriosis, mu opioid receptor (MOR) expression decreased by 20% and NMDA receptor (NR1) profiles decreased by 40% in the ventral PAG, despite no changes in endogenous opioid peptide levels (met-enkephalin, leu-enkephalin, and β-endorphin).
This means endometriosis doesn't reduce the brain's supply of natural painkillers — it reduces the receptors they need to work through. With fewer opioid receptors in the PAG, the brain's natural pain-dampening system becomes less effective, potentially explaining why endometriosis pain is so persistent and difficult to treat.
Why it matters
Endometriosis affects an estimated 10% of reproductive-age women and is notorious for causing severe, chronic pain that responds poorly to standard treatments. This study reveals that endometriosis physically rewires the brain's pain-modulation circuitry by downregulating key receptors. Understanding this central sensitization mechanism could explain why opioid painkillers often become less effective over time in endometriosis patients and could guide the development of more targeted pain therapies.
The numbers in context
60-day endometriosis model · 20% decrease in MOR-expressing neurons · 40% decrease in NR1-expressing neurons · No change in met-enkephalin, leu-enkephalin, or β-endorphin levels · Ventral PAG specifically affected
How the study worked
Researchers induced endometriosis in female Sprague-Dawley rats using the autotransplantation model (surgically relocating uterine tissue to create endometriotic lesions). After 60 days of disease progression, brain tissue was collected and the periaqueductal gray was analyzed using immunohistochemistry to quantify endogenous opioid peptides (met-enkephalin, leu-enkephalin, β-endorphin), mu opioid receptors, and NMDA NR1 receptor expression.
Who was studied
Female Sprague-Dawley rats with surgically induced endometriosis (60-day model)
What this study cannot tell us
The autotransplantation rat model doesn't perfectly replicate human endometriosis — the disease originates differently and the hormonal milieu differs. The study examined a single timepoint (60 days) and didn't assess whether these brain changes correlate with behavioral pain measures. The sample size isn't stated in the abstract. Whether these receptor changes are reversible with endometriosis treatment is unknown.
How to read the evidence
This is a well-designed animal study using a validated rat model of endometriosis with specific neuroanatomical and immunohistochemical analysis. While the mechanistic findings are compelling, translation from rat PAG to human pain processing involves uncertainty. The lack of behavioral pain correlation and unspecified sample sizes are limitations.
When this study was published
Published in 2016, this study was among the first to directly examine opioid receptor changes in the brain caused by endometriosis. The findings remain relevant and have been supported by subsequent research on central sensitization in endometriosis.
The bigger picture
Chronic pain in endometriosis has traditionally been viewed as coming from the pelvic lesions themselves. This study adds to growing evidence that endometriosis causes central nervous system changes — the brain itself is altered. This concept of 'central sensitization' is reshaping how we understand and treat chronic pain conditions. It suggests that treating endometriosis pain may require addressing not just the pelvic disease but also the brain changes it causes.
Questions still open
- If endometriosis treatment removes the pelvic lesions, do the brain opioid receptor changes reverse, or has permanent central sensitization occurred?
- Could drugs that upregulate opioid receptor expression in the PAG provide more targeted pain relief for endometriosis patients?
- Does the 40% NMDA receptor reduction contribute to the well-documented difficulties with ketamine and other NMDA-targeting pain therapies in chronic pain patients?
Common questions
Why is endometriosis pain so hard to treat?
Does this mean opioid painkillers won't work well for endometriosis?
Read the original research
Endometriosis Is Associated With a Shift in MU Opioid and NMDA Receptor Expression in the Brain Periaqueductal Gray.
Reproductive sciences (Thousand Oaks, Calif.), 23(9), 1158-67
Citation
Torres-Reverón, Annelyn; Palermo, Karylane; Hernández-López, Anixa; Hernández, Siomara; Cruz, Myrella L; Thompson, Kenira J; Flores, Idhaliz; Appleyard, Caroline B. (2016). Endometriosis Is Associated With a Shift in MU Opioid and NMDA Receptor Expression in the Brain Periaqueductal Gray.. Reproductive sciences (Thousand Oaks, Calif.), 23(9), 1158-67. https://doi.org/10.1177/1933719116630410